000 01625 a2200421 4500
005 20250515120353.0
264 0 _c20090331
008 200903s 0 0 eng d
022 _a1460-2377
024 7 _a10.1093/intimm/dxn036
_2doi
040 _aNLM
_beng
_cNLM
100 1 _aJin, Gui-Hua
245 0 0 _aCombination treatment with IL-2 and anti-IL-2 mAbs reduces tumor metastasis via NK cell activation.
_h[electronic resource]
260 _bInternational immunology
_cJun 2008
300 _a783-9 p.
_bdigital
500 _aPublication Type: Journal Article; Research Support, Non-U.S. Gov't
650 0 4 _aAnimals
650 0 4 _aAnimals, Genetically Modified
650 0 4 _aAntineoplastic Combined Chemotherapy Protocols
_xadministration & dosage
650 0 4 _aCD8-Positive T-Lymphocytes
_xdrug effects
650 0 4 _aDendritic Cells
_xdrug effects
650 0 4 _aG(M1) Ganglioside
_ximmunology
650 0 4 _aHeparin-binding EGF-like Growth Factor
650 0 4 _aImmunity, Cellular
650 0 4 _aImmunotherapy
650 0 4 _aIntercellular Signaling Peptides and Proteins
_xgenetics
650 0 4 _aInterleukin-2
_xantagonists & inhibitors
650 0 4 _aKiller Cells, Natural
_xdrug effects
650 0 4 _aLung Neoplasms
_ximmunology
650 0 4 _aMelanoma, Experimental
_ximmunology
650 0 4 _aMice
650 0 4 _aNeoplasm Metastasis
650 0 4 _aNeoplasm Transplantation
700 1 _aHirano, Toshio
700 1 _aMurakami, Masaaki
773 0 _tInternational immunology
_gvol. 20
_gno. 6
_gp. 783-9
856 4 0 _uhttps://doi.org/10.1093/intimm/dxn036
_zAvailable from publisher's website
999 _c17944825
_d17944825